NESS06SM, a peripherally selective CB1R neutral antagonist whose structure is related to rimonabant, was found to be efficacious in ameliorating diet- and olanzapine-induced obesity and its metabolic abnormalities [136,137]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.